摘要
目的评价Middlebrook7H11斜面培养基用于临床样本分枝杆菌培养的效果。方法收集上海市公共卫生临床中心住院和门诊患者各类临床样本599例,分别采用Middlebrook7H11斜面培养基和罗氏培养基培养分枝杆菌,比较2种培养基培养阳性率、报阳时间和污染率差异。结果599例样本中,Middlebrook7H11斜面培养基培养阳性率为12.9%(77例),罗氏培养基培养阳性率为12.4%(74例),两者联合培养阳性率为15.0%(90例)。Middlebrook7H11斜面培养基培养阳性率稍高于罗氏培养基,但差异无统计学意义(χ^(2)=0.07,P>0.05);罗氏培养基污染率高于Middlebrook7H11斜面培养基(χ^(2)=4.67,P<0.05);Middlebrook7H11斜面培养基报阳时间比罗氏培养基短1周,阳性早出现1周的例数多于罗氏培养基(χ^(2)=11.62,P<0.01)。结论Middlebrook7H11斜面培养基用于分枝杆菌培养优于罗氏培养基,两者联合培养可提高阳性率。
Objective To evaluate Middlebrook7H11 slant medium for culturing Mycobacterium from clinical specimens.Methods Totally,599 clinical specimens of inpatients and outpatients in Shanghai Public Health Clinical Center were cultured by Middlebrook7H11 slant medium and Löwenstein-Jensen medium.The positive rates,positive occurrence times and contamination rates of the 2 media were compared.Results Of the 599 clinical specimens,77(12.9%)cases were positive for Middlebrook7H11 slant medium,and 74(12.4%)cases were positive for Löwenstein-Jensen medium.The combined positive rate was 15.0%(90 cases).There was no statistical significance in the positive rates between Middlebrook7H11 slant medium and Löwenstein-Jensen medium(χ^(2)=0.07,P>0.05).The contamination rate of Löwenstein-Jensen medium was higher than that of Middlebrook7H11 slant medium(χ^(2)≤4.67,P<0.05).The positive occurrence time of Middlebrook7H11 slant medium was 1 week shorter than that of Löwenstein-Jensen medium,and the number of positive clinical specimens appeared earlier than that of Löwenstein-Jensen medium(χ^(2)≤11.62,P<0.01).Conclusions Middlebrook7H11 slant medium is superior to Löwenstein-Jensen medium in Mycobacterium culturing.The combined determination of the 2 media can improve the positive rate.
作者
钱雪琴
卢洪洲
QIAN Xueqin;LU Hongzhou(Department of Clinical Laboratory,Shanghai Public Health Clinical Center,Shanghai 201508,China;Department of Infection and Immunology,Shanghai Public Health Clinical Center,Shanghai 201508,China)
出处
《检验医学》
CAS
2021年第5期519-523,共5页
Laboratory Medicine
基金
国家“十三五”艾滋病和病毒性肝炎等重大传染病防治科技重大专项资助项目(2017ZX10202101-002)。